Overview

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2028-05-15

Target enrollment:

Participant gender:

Summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with tislelizumab in participants with advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

BeiGene

Treatments:

tislelizumab